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Abstract 
The left dorsolateral prefrontal cortex (DLPFC) is involved in the experience and modulation of pain, and 
may be an important node linking pain and cognition. Repetitive transcranial magnetic stimulation 
(rTMS) to the left DLPFC can reduce chronic and experimental pain. However, whether left DLPFC rTMS 
can influence the development of chronic pain is unknown. Using repeated intramuscular injection of 
nerve growth factor (NGF) to induce the development of sustained muscle pain (lasting weeks), thirty 
healthy individuals were randomized to receive 5 consecutive daily treatments of active or sham left 
DLPFC rTMS, starting before the first NGF injection on day 0. Muscle soreness and pain severity were 
collected daily for 14 days and disability on every alternate day. Before the first and one day after the 
last rTMS session, anxiety, depression, affect, pain catastrophizing and cognitive performance on the 
attention network test were assessed. Left DLPFC rTMS treatment compared to sham was associated 
with reduced muscle soreness, pain intensity, and painful area (p<0.05), and a similar trend was 
observed for disability. These effects were most evident during the days rTMS was applied lasting up to 
three days following intervention. Depression, anxiety, pain catastrophizing, and affect were unchanged. 
There was a trend toward improved cognitive function with rTMS compared to sham (p=0.057). These 
data indicate that repeated left DLPFC rTMS reduces the pain severity in a model of prolonged muscle 
pain. The findings may have implications for the development of sustained pain in clinical populations. 
Keywords: pain; repetitive transcranial magnetic stimulation; nerve growth factor; brain 
stimulation; transition  
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Summary 
Repetitive transcranial magnetic stimulation (rTMS) of left dorsolateral prefrontal cortex (DLPFC), 
compared to sham stimulation, reduces pain development in a long-lasting model of muscle pain. 
 
Introduction 
Musculoskeletal pain disorders are the largest contributors to global years lived with disability [23]. 
Consequently, effective and affordable strategies are urgently required to deal with this rising problem. 
Our previous work has demonstrated disruption of brain cognitive networks with acute pain and with 
chronic pain [12;13;31;35;37;38] and we further proposed a role for cognitive network dysfunction in 
chronic pain disorders and possible treatments [34]. The dorsolateral prefrontal cortex (DLPFC) – 
particularly the left DLPFC – has been implicated in pain experience and modulation, and could be a 
major node mediating the interaction between pain and cognition [36]. For example, patients have 
shown altered abnormal cognitive-related activity in the left DLPFC when performing conflict tasks such 
as the attention network test [31;38]. This suggests that targeting DLPFC function could have effects on 
both pain and cognitive function, as well as their interaction.   
Repetitive transcranial magnetic stimulation (rTMS) of the left DLPFC has been used with some success 
for the treatment of chronic pain conditions including migraine [11], burning mouth syndrome [47], post 
traumatic headache [27], post-operative pain [8;9], and fibromyalgia where analgesic effects were 
similar to those of FDA approved pharmaceuticals with fewer side-effects [30]. Left DLPFC rTMS has an 
immediate analgesic effect for prolonged capsaicin-induced pain in healthy subjects and the 
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mechanisms of action appear to depend on widespread cortical network effects and activation of the 
endogenous opioid system [45;46]. Left DLPFC rTMS also modulates dopaminergic [14] and serotonergic 
systems [39], which could also potentially modulate pain. Right DLPFC rTMS analgesia does not involve 
an endogenous opioid mechanism [17] and might be related to glutamatergic modulation [16]. Left – 
but not right – DLPFC rTMS reduced bilateral capsaicin pain intensity when delivered 10-20 min after 
capsaicin application and the analgesic effects was found after 20-30 min [10;45;46]. In line with this 
finding, left DLPFC rTMS increased heat pain thresholds and reduced heat hyperalgesia by capsaicin, but 
had no effect on cold pain thresholds [46]. Left DLPFC rTMS has also been shown to reverse motor 
cortex inhibition during capsaicin-induced pain in healthy participants [22]. However, the mechanisms of 
rTMS for pain are still the subject of considerable debate [20], in particular regarding the timing of rTMS 
with respect to the nociceptive event, type of pain, and duration of the analgesic effect.  
Pain models have been used to study the effects of pain lasting minutes to hours (e.g. topical capsaicin) 
in healthy participants. However, to understand the development of sustained muscle pain, longer-
lasting prolonged pain models are needed. Intramuscular injections of nerve growth factor (NGF) 
induces deep-tissue pain and hyperalgesia for days to weeks [1;4;44] with motor cortical adaptations 
[25;33].            
In the present study, we randomized healthy subjects to receive left DLPFC rTMS over five days or sham 
rTMS to test whether rTMS could reduce pain intensity and distribution, as well as improve cognitive 
task performance, in a long-lasting (up to fourteen days) model of NGF-induced muscle pain. We 
hypothesized that left DLPFC rTMS would reduce prolonged muscle pain and improve performance on a 
cognitive task, relative to sham.   
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Materials and Methods 
Participants 
Thirty healthy right-handed subjects (18 female; 12 male) participated in this randomized controlled 
study, recruited through online advertising and flyers posted at Aalborg University. All participants were 
naïve to single pulse and repetitive TMS prior to enrolment, and had no history of chronic pain, 
neurological disorders and psychiatric disorders. Fifteen participants (9 females for each group) were 
randomly assigned to each of the active or sham rTMS groups. Inclusion criteria: healthy men and 
women aged 21-50 years; speak and understand English. Exclusion criteria: pregnancy; drug addiction 
defined as the use of cannabis, opioids or other drugs; previous neurologic, musculoskeletal or mental 
illnesses; lack of ability to cooperate; history of chronic pain or current acute pain; previous experience 
with rTMS; contraindications to rTMS application (history of epilepsy, metal in the head or jaw etc.); 
failure to pass the Transcranial Magnetic Stimulation Adult Safety Screen (TASS) (Rossi et al., 2011). 
Before starting experimental procedures a physical examination was performed to check the presence 
of full pain free range of elbow and wrist motion, and the absence of tenderness to palpation of the soft 
tissues in the extensor muscles of the wrist. The study was approved by the local Ethics Committee (N-
20170041) and was performed in accordance with the Helsinki Declaration. Written informed consent 
was obtained prior to study commencement.  
Study protocol 
The study involved 6 sessions on 6 consecutive days (day 0 to day 5), plus online daily diaries completed 
up to day 14. Randomization occurred on day 0 before any assessments. Randomization was based on a 
predetermined, randomly generated order. Questionnaires were collected at the beginning of the 
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sessions on days 0 and 5. Other data collected as part of the protocol that will be reported elsewhere 
include motor evoked potentials, somatosensory evoked potentials, electroencephalography during 
cognitive task performance, quantitative sensory and motor assessment (pressure pain thresholds and 
wrist extensor force).  On day 0 and day 2 participants received an injection of NGF into the right 
extensor radialis carpi brevis (ECRB) muscle in order to develop muscle pain along the radial site of the 
right forearm. After assessments at day 0, day 1, day 2, day 3, and day 4 participants received 20 
minutes of active or sham high-frequency rTMS on the DLPFC. On day 0 and day 2 the real or sham rTMS 
occurred prior to the NGF injection.  
Questionnaires 
At day 0 and day 5, participants completed the following questionnaires: 1) State-Trait Anxiety Inventory 
(STAI-S, STAI-T)[41]; 2) Pain Catastrophizing Scale (PCS)[42;43]; 3) Beck Depression Inventory (BDI-II)[3]; 
4) Positive and Negative Affective Schedule (PANAS)[15;48].  
The area of pain was assessed using body chart drawings at days 1-5, 9, and 14 [40]. Participants drew 
the distribution of their NGF-induced pain on an anatomical drawing of the upper limb. The areas of the 
body chart drawings were calculated in arbitrary units (a.u.) using a scanning program (VistaMetrix, 
v.1.38.0; SkillCrest, LLC, Tucson, AZ). 
Online diaries regarding muscle soreness and pain severity were completed on days 0 to 14. Muscle 
soreness was assessed using a modified 7-point Likert scale; 0 = ‘a complete absence of soreness’, 1 = ‘a 
light soreness in the muscle felt only when touched/vague ache’, 2 = ‘a moderate soreness felt only 
when touched/a slight persistent ache’, ‘3 = ‘a light muscle soreness when lifting or carrying objects’, 4 = 
‘a light muscle soreness, stiffness or weakness when moving the wrist without gripping an object’, 5 = ‘a 
moderate muscle soreness, stiffness or weakness when moving the wrist’, 6 = ‘a severe muscle soreness, 
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stiffness or weakness that limits the ability to move’. Pain severity was assessed on an 11-point 
numerical rating scale (0 = no pain, 10 = most intense pain imaginable). The Patient-rated Tennis Elbow 
Evaluation Questionnaire (PRTEEQ; [29], used to assess average pain and disability of the injected arm, 
was completed on days 0, 3, 5, 9, and 14.  
Repetitive TMS procedures 
Repetitive transcranial magnetic stimulation (rTMS) was delivered using a figure-of-eight shaped coil 
(70mm Double Air Film Coil; Magstim Super Rapid2 Plus1, Magstim Co. Ltd, Dyfed, UK). The rTMS 
protocol consisted of one session per day for 5 consecutive days. Each 20-minute stimulation session 
consisted of 80 trains of 5-second pulses with a frequency of 10 Hz and an interval of 10 seconds 
between each train, giving a total of 4000 pulses per day [46]. The stimulation intensity was 110% of the 
resting motor threshold (rMT) of the first dorsal interosseous (FDI) muscle and the coil was located 
according to the BeamF3 algorithm [2;32]. The BeamF3 algorithm takes as input three scalp 
measurements: the nasion-inion distance, the left tragus-right tragus distance through the scalp vertex, 
and the head circumference measured through the FPz-Oz plane in the international 10–20 EEG system. 
These values were entered into the freely available BeamF3 desktop application 
(clinicalresearcher.org/software.htm) in order to generate the coordinates to locate the rTMS coil. Sham 
stimulation was carried out with a sham coil of identical size, color, and shape, emitting a sound similar 
to that emitted by the active coil (70mm Double Air Film Sham Coil). Procedures and instructions to 
participants in the rTMS and sham groups were identical. Because the rTMS procedure is known to be 
painful, pain ratings were acquired at the end of each rTMS/sham session [7], using a 0 to 10 numerical 
rating scale (NRS) for pain intensity, where 0 was no pain and 10 was most intense pain imaginable.  AC
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NGF-induced muscle soreness  
Muscle pain and hyperalgesia were induced by repeated injection of NGF into the ECRB muscle, which 
models lateral epicondylalgia [4]. Sterile solutions of recombinant human Beta-NGF were prepared by 
the pharmacy (Skanderborg Apotek, Denmark). NGF injections occurred on day 0 and day 2. The site of 
injection was cleaned with alcohol, and NGF solution (5µg/0.5 mL) was injected into the muscle belly of 
ECRB, guided in-plane under real-time ultrasound guidance (SonoSite M-Turbo, FUJIFILM SonoSite, Inc. - 
US).  
Cognitive task  
Participants performed the Attention Networks Test (ANT) [21] on day 0 and day 5. This task assesses 
cognitive function in three domains: alerting, orienting, and executive function (conflict resolution). 
Participants performed the task in six blocks of 5 minute according to the procedure previously reported 
[21]. Briefly, the task implemented in E-prime (version 3.0) involves the presentation of an arrow and 
the correct response is the direction of that arrow, indicated by the button on the participant’s right-
hand middle (right) or index (left) finger. Around the arrow, two arrows can be presented on each side, 
which can point in the same direction (congruent) or opposite direction (incongruent) of the center 
target arrow. Additional cues are given prior the target stimuli and are related to alerting in orienting. 
Reaction times were used as the performance measure in the task. Only the conflict (difference between 
congruent and incongruent reaction time) was examined, as these measures previously have been 
reported in the context of acute and chronic pain [31;37;38], where increased brain resources have 
been shown to be recruited.  AC
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Statistical analysis  
All data are presented as mean and standard error of the mean (SEM). All data from all assessments 
were normality tested using visual inspection and the Shapiro-Wilk’s test.  A mixed-model analysis of 
variance (ANOVA) was used for all parameters to assess effects of day (days 0 to 14 for muscle soreness 
and pain intensity, and days 0, 5, 9, and 14 for other measures), group (rTMS, sham), and day-by-group 
interaction, where the factor day was repeated measures and group was between group comparisons. 
For procedural NRS pain scores, a one-way repeated-measure ANOVA was used with time as main 
factor. We further tested the association between procedural pain and muscle soreness and pain 
intensity the next day using Pearson correlations. Correcting against violations of sphericity, the 
Greenhouse-Geisser approach was used. Effect sizes (partial eta-squared (η2p)) are reported for 
significant effects. Where appropriate, post-hoc analyses were performed using Bonferroni multiple 
comparison tests. Statistical significance was set at P < 0.05. 
 
Results 
Demographics 
The sample sizes, sex, age, height, and weight for the sham and active groups are shown in Table 1. 
Groups were matched for sex (6 male, 9 females in each group). All subjects performed all sessions and 
no data were missing. Resting motor threshold assessed on days 0 and 5 were (mean ± S.D.) sham, day 0 
42.9 ± 10.0, sham day 5 41.7 ± 8.7, active day 0  42.9 ± 11.0, active day 5 43.9 ± 9.6.  
 
 
AC
CE
PT
ED
Copyright  8 8 by the International Association for the Study of Pain. Unauthorized reproduction of this article is prohibited.            201
9 
 
 
 
 
 
 
Left DLPFC rTMS reduced pain and muscle soreness 
Means and standard deviations for all outcomes are reported in Supplementary Table S1 (available 
athttp://links.lww.com/PAIN/A636). The rTMS group had lower muscle soreness ratings (group main 
effect: F1,28=8.8, p=0.006, η2p=0.24; group-by-time interaction: F4.1,392=4.5, p=0.002, η2p=0.14, Fig 1A) 
and pain intensity NRS ratings (group main effect: F1,28=6.3, p=0.018, η2p=0.19; group-by-time 
interaction: F2.9,392=2.5, p=0.068, η2p=0.09, Fig 1B) than the sham group. Post-hoc tests revealed that 
differences in muscle soreness Likert scores were apparent at 2, 4, 5, 6, and 7 days following the first 
NGF injection, (p<0.05). Because these Likert score data were non-normally distributed, we also 
performed Kruskal-Wallis tests and found the same as the parametric tests (i.e. days 2, 4, 5, 6, and 7 
were different between groups). The rTMS group also had a similar, but non-significant trend toward 
reduced disability as assessed by the PRTEEQ, which was apparent by day 5 (group main effect: F1,28=2.5, 
p>0.1, η2p=0.08 ; group-by-time interaction: F1.4,112=2.1, p>0.1, η2p=0.07, Fig 1C). Area of pain based on 
body map drawings was lower in the real rTMS compared to sham group (group main effect: F1,28=9.6, 
p=0.004, η2p=0.26; group-by-time interaction: F3.4,168=4.1, p=0.006, η2p=0.13, Fig 1D), and post-hoc 
tests indicated significant differences at days 3 and 5 (p<0.05). 
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Left DLPFC rTMS showed a trend towards improved cognitive task performance 
The rTMS group had a marginally greater reduction in conflict cost (i.e., improved performance in 
reaction time) compared to sham at day 5 compared to baseline (group main effect: F1,28=1.1, p>0.2, 
η2p=0.04; group-by-time interaction: F1,28=3.9, p=0.057, η2p=0.12). This represented a conflict reaction 
time cost reduction from 96.5 ± 6.8 ms at baseline to 74.8 ± 4.2 ms at day 5 in the rTMS group, versus a 
reduction from 97.4 ± 4.9 ms to 89.9 ± 7.1 ms in the sham group. There were no differences between 
rTMS and sham groups on the alerting (41.7 ± 4.1 ms at baseline to 49.4 ± 5.3 at day 5 for rTMS group 
versus 34.8 ± 6.3 ms at baseline to 46.1 ± 7.1 at day 5 for sham group;  group main effect: F1,28=0.5, 
p>0.5; group-by-time interaction: F1,28=0.2, p>0.5) and orienting components of the task (27.3 ± 3.7 ms 
at baseline to 25.6 ± 4.3 at day 5 for rTMS group versus 33.5 ± 5.8 ms at baseline to 29.2 ± 3.6 at day 5 
for sham group;  group main effect: F1,28=0.9, p>0.3; group-by-time interaction: F1,28=0.1, p>0.5).   
No effects of left DLPFC rTMS on anxiety, depression, affect, or pain catastrophizing  
There was no difference between groups in terms for state anxiety (group main effect: F1,28=0.3, p>0.5; 
group-by-time interaction: F1,28=0.3, p>0.5) or trait anxiety (group main effect: F1,28=0.05, p>0.5; group-
by-time interaction: F1,28=0.4, p>0.5), depression (group main effect: F1,28=0.4, p>0.5; group-by-time 
interaction: F1,28=0.9, p>0.3), pain catastrophizing (group main effect: F1,28=1.2, p>0.2; group-by-time 
interaction: F1,28=0.6, p>0.4), or positive affect (group main effect: F1,28=0.003, p>0.5; group-by-time 
interaction: F1,28=1.2, p>0.2) or negative affect (group main effect: F1,28=3.0, p>0.1; group-by-time 
interaction: F1,28=0.1, p>0.5) on the PANAS. These characteristics are reported in Table 1.  
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rTMS procedural pain 
The rTMS intensity used in this study was 60.1±2.5. Procedural NRS pain ratings and rTMS intensity 
correlated (Pearson r= 0.56, p<0.05). Procedural NRS pain ratings steadily decreased across days, from 
5.6±0.8 on day 0 to 4.2±0.7, 3.8±0.6, 3.5±0.6, 2.9+0.6 for days 1 through 4, respectively (F1.87,52=8.8, 
p=0.002, η2p=0.40), indicating that pain was reduced over time, consistent with previous reports. 
Furthermore, Pearson correlations revealed no relevant relationship between lower NGF-pain with 
higher procedural pain the previous day. The sham procedure was never painful. No side effects were 
reported and the treatment was well tolerated by all participants.  
 
Discussion 
The present results show that 5-days of treatment with left DLPFC high frequency (excitatory) rTMS can 
reduce the pain intensity, distribution, and muscle soreness associated with long-lasting experimental 
muscle pain. Moreover, no significant effect on depression, anxiety, pain catastrophizing, or affect 
scores was found due to rTMS, although a near-significant improvement in cognitive task performance 
was observed. The NGF-induced muscle pain model is thought to closely reflect the period of acute pain 
prior to the transition to chronic pain [4;33]. Since pain intensity is a strong predictor of the transition to 
chronic pain [26], interventions like left DLPFC rTMS that reduce pain during the early periods of 
development have the potential clinical application of preventing the persistent pain following injury or 
surgery.  
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Effects of DLPFC rTMS on pain 
The mechanisms by which left DLPFC rTMS produce analgesia are yet unclear, but growing evidence 
points to the left DLPFC as an important region in pain experience and modulation [36]. While one study 
has shown that left DLPFC rTMS reduces post-operative pain, the stimulation was carried out following 
surgery [8]. It has yet to be tested whether rTMS prior to surgery can prevent the development of acute 
and chronic pain. Left DLPFC rTMS has shown promise for a number of chronic pain conditions, including 
migraine [11], post-traumatic headache [27], fibromyalgia [30], and burning mouth syndrome [47], 
although for central post-stroke pain it has been shown to be ineffective [18]. Left DLPFC rTMS could 
thus be an effective treatment for pain or pain prevention. In the current study, effects of rTMS were 
strongest on the later days of intervention and three days afterward (i.e. days 2-7), whereas minimal 
differences between active and sham groups were seen late (i.e. days 8-14). Further studies employing 
DLPFC rTMS are required to determine if a longer intervention period would have longer-lasting effects. 
One mechanism of left DLPFC rTMS analgesia could be activation of the descending modulatory 
endogenous opioidergic system [45;46], although the involvement of glutamatergic, dopaminergic, and 
serotonergic systems is also plausible [14;16;39].  
High frequency rTMS of the left DLPFC is an effective treatment for major depressive disorder [24]. The 
effects on mood present another means by which left DLPFC rTMS could have analgesic effects 
[5;6;27;49]. We found no effect of left DLPFC rTMS on positive or negative affect, anxiety, or depression, 
which could have been a result of either the low scores on these questionnaires given the healthy 
participants involved, or the shorter period of intervention compared to typical clinical protocols for 
depression (weeks).  
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Effects of DLPFC rTMS on cognitive function 
Another possibility is that the analgesic effects derived from left DLPFC rTMS occur through modulation 
of cognitive function [34;36]. Previous work has shown the left DLPFC stimulation can modulate 
cognitive function. For example, a recent study reported that transcranial direct current stimulation 
(tDCS) over the left DLPFC improved performance on a working memory task, which was also associated 
with a reduction in simultaneous pain evoked with an electrical stimulus [19]. Improved performance on 
a Stroop task was also reported following 7 days of high frequency left DLPFC rTMS [28]. We therefore 
assessed cognitive function on a similar cognitive task involving cognitive conflict and found that left 
DLPFC rTMS was associated with an improvement in cognitive task performance compared to sham, 
although this effect failed to reach statistical significance, possibly because the stimulation was not 
repeated for enough days or the sample size was too small. Previous work has shown that in chronic 
pain conditions, cognitive-related activation of the left DLPFC is increased relative to healthy controls 
[31;38] and following treatment, activation and connectivity of the left DLPFC normalizes [13;38]. While 
the relationship between left DLPFC function and pain is unclear, more extensive follow-up studies on 
the interaction between DLPFC stimulation, cognitive function, and pain are warranted.  
Limitations 
There were some notable limitations to the study. First, while our sample size was greater than in 
previous studies on left DLPFC for acute [46] or chronic [47] pain, it was fairly small. While the main 
outcomes of the study were significant, others, such as the disability and cognitive function, showed a 
non-significant trend. These effects are likely to reach significance with a slightly larger sample. Second, 
as has been reported previously, DLPFC rTMS is painful and decreases over sessions [7]. We observed 
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similar procedural pain intensity and decrease in procedural pain over time as previously reported 
[7;47]. This reduction over time has been interpreted as an analgesic effect of the rTMS, rather than 
habituation to the stimulation over time because the sham procedural pain evoked with electrical 
stimulation below the sham coil in that study did not show a change over time [7]. In addition, because 
our measures of pain related to the NGF were acquired a day after intervention, it seems unlikely that 
differences between sham and rTMS would be related to procedural pain. Another possible limitation is 
that the stimulation we used was at 110% of the baseline rMT, rather than re-acquiring rMT at each 
session. This is similar to other protocols[28]. While rMT is likely to change with the NGF model, 
whether this affects DLPFC response is unknown. A final limitation is that the study was single blind: 
while participants did not know whether they received real or sham rTMS, the experimenter involved in 
data collection was not blinded.   
Conclusion 
Five days of left DLPFC rTMS reduced the development of ongoing pain induced by an NGF-induced 
muscle pain model compared with the sham rTMS. These changes lasted at least three days after the 
intervention period and occurred in the absence of changes in mood, affect, anxiety, or pain 
catastrophizing. A trend of improved cognitive performance was also seen in active compared to sham 
rTMS. Overall this study provides early evidence for the use of left DLPFC rTMS for preventing the 
development of pain shortly after tissue trauma. 
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Figure legend 
 
Figure 1. Mean (± SEM, N = 15) Likert scores of muscle soreness (A), pain intensity NRS scores 
(B), PRTEEQ (Patient-rated Tennis Elbow Evaluation Questionnaire) scores (C), and pain area 
(body map) (D) following NGF injections on day-0 and day-2 in groups receiving active and 
sham rTMS. Note that rTMS occurred on days 0, 1, 2, 3, and 4. * Significant Bonferroni-
corrected post-hoc tests for analyses with significant group-by-time interactions (P<0.05). Ŧ 
Significant main effect of group. 
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Table 1. Participant characteristics.  
 Active rTMS group Sham rTMS group 
Sample size 15 15 
Sex (M, F) 6, 9 6, 9 
Age (years) 26.9 ± 1.0 26 ± 1.4 
Height (cm) 170 ± 2.2 172 ± 2.9 
Weight (kg) 69 ± 3.5 75 ± 4.7 
 Day 0 Day 5 Day 0  Day 5 
Depression (BDI-II) 5.7 ± 1.6 5.1 ± 1.4 7.2 ± 2.3 7.4 ± 2.6 
State Anxiety (STAI-S) 42.0 ± 1.4 41.3 ± 1.6 40.5 ± 1.2 40.6 ± 1.6 
Trait Anxiety (STAI-T) 47.2 ± 0.8  46.5 ± 1.1 46.5 ± 1.3 46.6 ± 1.0 
Pain Catastrophizing Scale 15.8 ± 2.3 12.6 ± 2.5 11.9 ± 2.2 11.6 ± 2.3 
PANAS-negative 12.7 ± 0.6 12.2 ± 0.5 11.5 ± 0.5 11.3 ± 0.5 
PANAS-positive 28.1 ± 2.2 26.9 ± 2.8 26.1 ± 2.1 28.7 ± 2.5 
STAI, state-trait anxiety inventory; PANAS, positive and negative affective schedule. BDI-II, Beck 
Depression Inventory. 
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